REGIONAL AND MULTIFACTORIAL PATTERNS OF INFLAMMATORY BOWEL DISEASE IN BRAZIL: A SYSTEMATIC ANALYSIS OF HOT SPOTS IN WESTERN SÃO PAULO AND PARANÁ.

Arq GastroenterolSep 21, 2026 (epub)
Clinical ResearchGastroenterologyPreventive Medicine / Public Health

Abel Botelho Quaresma, Fabio V Teixeira, Douglas A Valverde et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed the epidemiology of Inflammatory Bowel Disease (IBD) in Brazil, focusing on hot spots in Western São Paulo and Northwestern Paraná. The study found that over 85% urbanization, agro-industrial activity, and dietary changes contribute to increased IBD prevalence in these regions. The review highlights significant diagnostic disparities affecting data accuracy.

Key findings

  • Identified IBD hot spots in Western São Paulo and Northwestern Paraná with over 85% urbanization.
  • Increased IBD prevalence linked to genetic predisposition, Westernized diets, and reduced microbial exposure.
  • Diagnostic infrastructure disparities lead to underreporting in less developed regions.

Why it matters

Understanding regional patterns of IBD can inform public health policies and resource allocation. Addressing environmental and dietary factors may improve disease management and prevention strategies in affected areas.

Source

PubMed · PMID 42788522

Published in Arq Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.